Saturday, October 31, 2026

Nasdaq Inc Stock Bearish Momentum With A 11% Fall So Far Today

Nasdaq Inc Stock Bearish Momentum With A 11% Fall So Far Today

(VIANEWS) - Shares of Nasdaq Inc (NASDAQ: NDAQ) dropped by a staggering 11.02% to $51.46 at 14:27 EST on Monday, after two sequential sessions in a row of gains. NASDAQ is jumping 0.99% to $13,390.09, after two consecutive sessions in a row of gains. This seems, at the moment, a somewhat bullish trend exchanging session today.

Nasdaq Inc's last close was $57.83, 16.45% under its 52-week high of $69.22.

About Nasdaq Inc

Nasdaq, Inc. operates as a technology company that serves capital markets and other industries worldwide. It operates in three segments: Market Platforms, Capital Access Platforms, and Anti-Financial Crime. The Market Platforms segment trading services, including equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing, and trade management service businesses. This segment operates various exchanges and other marketplace facilities across various asset classes, which include derivatives, commodities, cash equity, debt, structured products, and exchange traded products; and provides broker, clearing, settlement, and central depository services. This segment also handles assets, such as cash equities, equity derivatives, currencies, interest-bearing securities, commodities, energy products, and digital currencies. The Capital Access Platforms segment sells and distributes historical and real-time market data; develops and licenses Nasdaq-branded indexes and financial products; operates listing platforms; investment insights and workflow solutions; and offers investor relations intelligence, ESG solutions, and governance solutions. The Anti-Financial Crime segment includes anti financial crime management solutions, which offers Nasdaq Trade Surveillance, a SaaS solution for brokers and other market participants to assist them in complying with market rules, regulations, and internal market surveillance policies; Nasdaq Market Surveillance, a market surveillance solution for markets and regulators; and Verafin, a SaaS technology provider of anti-financial crime management solutions. The company was formerly known as The NASDAQ OMX Group, Inc. and changed its name to Nasdaq, Inc. in September 2015. Nasdaq, Inc. was founded in 1971 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, Nasdaq Inc has a trailing twelve months EPS of $2.3.

PE Ratio

Nasdaq Inc has a trailing twelve months price to earnings ratio of 22.37. Meaning, the purchaser of the share is investing $22.37 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 18.7%.

Volume

Today's last reported volume for Nasdaq Inc is 10923895 which is 319.49% above its average volume of 2604080.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nasdaq Inc's stock is considered to be oversold (<=20).

More news about Nasdaq Inc (NDAQ).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com